FDA Approves Abiomed's (ABMD) New AB Portable Driver; Providing Patient Transport, Mobility and Ambulation without Compromising Performance
More News related to ABMD
- Abiomed to Present at the 21st Annual Piper Jaffray Healthcare Conference
- Lazard Capital Downgrades Abiomed (ABMD) to Hold
- Abiomed (ABMD) Posts Q2 Loss of $0.21, In-Line with Estimates
- Abiomed Announces Record Revenue of $20 Million for Second Quarter of Fiscal 2010
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
More News related to Corporate News
- American International Group (AIG), Greenberg and Smith Settle Disputes
- Heska (HSKA) Announces Agreements with Roche for Blood Gas Product Supply/Affiliated Consumables
- AIG, Greenberg and Smith to settle all disputes
- DryShips (DRYS) Announces Exercise of Over-Allotment Option by Underwriters, Closes Convertible Senior Notes Offering for Net Proceeds of $448M
- Altra Holdings (AIMC) Closes $210M Senior Notes Offering; Enters Into Revolving Credit Facility; Subsidiary Tenders $167.9M of Senior Notes
Abiomed, Inc. (NASDAQ: ABMD) announced U.S. FDA approval of its Premarket Approval Application (PMA) supplement for the AB Portable(TM) driver. The FDA PMA approval permits the AB Portable driver to facilitate intra-facility patient transport, patient mobility for participation in physical and rehabilitation therapies, independent ambulation by the patient, and inter-hospital transport via aircraft or ambulance.
The new AB Portable driver offers a reliable cardiovascular support system, providing full Bi-Ventricular Assist Device (Bi-VAD) functionality. The new driver is designed to enhance the clinical utility of the Abiomed AB5000(TM) Ventricle by delivering direct benefits to both the hospital staff and patients by increasing mobility and versatility without compromising performance.
Related Categories
Corporate NewsFDA
Stocks Mentioned
-0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
